Ube2L3 Polyclonal Antibody, RBITC Conjugated

The ubiquitin (Ub) pathway involves three sequential enzymatic steps that facilitate the conjugation of Ub and Ub-like molecules to specific protein substrates. The first step requires the ATP-dependent activation of the Ub C-terminus and the assembly of multi-Ub chains by the Ub-activating enzyme known as the E1 component. The Ub chain is then conjugated to the Ub-conjugating enzyme (E2) to generate an intermediate Ub-E2 complex. The Ub-ligase (E3) then catalyzes the transfer of Ub from E2 to the appropriate protein substrate. UBE2E1 and UBE2L3, also designated UBCH6 and UBCH7 respectively in human, are E2 conjugating enzymes that interact with various proteins. Specifically, UBE2E1 interacts with the tumor suppressor protein TSSC5. UBE2L3 has been shown to mediate c-fos degradation, NF-kB maturation, human papilloma virus-mediated p53 and Myc protein degradation.

E2 F1; E2-F1; L UBC; L-UBC; UB2L3_HUMAN; UBCE7; UbcH7; UbcM4; Ube2l3; Ubiquitin carrier protein L3; Ubiquitin conjugating enzyme E2 L3; Ubiquitin protein ligase L3; Ubiquitin-conjugating enzyme E2 L3; Ubiquitin-conjugating enzyme E2-F1; Ubiquitin-protein ligase L3.